Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.58 USD
Change Today -0.33 / -3.02%
Volume 456.0K
ANTH On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:12 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) added to Russell 2000 Index

Anthera Pharmaceuticals, Inc. will be added to Russell 2000 Index

Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) added to Russell 3000 Index

Anthera Pharmaceuticals, Inc. will be added to the Russell 3000 Index.

Anthera Pharmaceuticals, Inc. Reaches Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial with Blisibimod

Anthera Pharmaceuticals, Inc. announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is expected in the second half of 2016. Results from CHABLIS-SC1, and eventually CHABLIS-SC2, are anticipated to support marketing approval for blisibimod as a treatment for active SLE that is not controlled by current best practice standard-of-care, including corticosteroids.

Anthera Pharmaceuticals, Inc. Announces Additional Data on Patient-Reported Outcomes from Phase 2B PEARL-SC Blisibimod Study

Anthera Pharmaceuticals, Inc. announced that additional data from its Phase 2b PEARL-SC study will be presented in a poster at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Rome, Italy. As part of a guided poster tour on June 6, 2015, Dr. Michelle Petri, Director of the Hopkins Lupus Center at Johns Hopkins University, will present breaking data on the impact of treatment with blisibimod on patient-reported fatigue and improvement in disease biomarkers.

Anthera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 03:30 PM

Anthera Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 03:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul F. Truex, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $10.58 USD -0.33

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies
 

Industry Analysis

ANTH

Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,228.8x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,573.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.